Remaxol

DRUG3 trials

Sponsors

POLYSAN Scientific & Technological Pharmaceutical Company

Conditions

CancerCholestasis, IntrahepaticDrug Induced Liver InjuryGallstone DiseaseObstructive Jaundice

Phase 2

Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis

CompletedNCT06183242

POLYSAN Scientific & Technological Pharmaceutical CompanyCholestasis, Intrahepatic

Start: 2023-05-27End: 2024-10-10Updated: 2025-04-29

Unknown Phase

Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy

CompletedNCT05789797

POLYSAN Scientific & Technological Pharmaceutical CompanyCancer, Drug Induced Liver Injury

Start: 2022-05-12End: 2024-12-16Updated: 2025-08-13

Remaxol® Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive Jaundice

CompletedNCT05928286

POLYSAN Scientific & Technological Pharmaceutical CompanyGallstone Disease, Obstructive Jaundice

Start: 2022-12-01End: 2025-12-31Updated: 2026-04-21